Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Clinical trial NCT03224819 · TERMINATED
Trial details
- NCT number
- NCT03224819
- Sponsor
- Amgen
- Status
- TERMINATED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-07
- Primary completion
- 2020-12-28
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.